4775 Peachtree Industrial Boulevard
Building 300, Suite 300
381 articles with Elekta
Elekta (EKTA-B.ST) announced today that its Geneva Universal Gynecological Applicator recently received U.S. FDA 510(k) clearance, enabling individuals with cervical cancer in the United States to benefit from the applicato
Recognition honors companies that take the long view with a purpose-based strategy and strive to create positive change throughout their global communities
First in Switzerland to offer patients a transformative approach to precision radiation medicine
Elekta Infinity and Elekta Synergy systems to alleviate China's burden of cancer
FDA Approves Diffusion-Weighted Images for Elekta Unity, Expanding Options for Assessment During Therapy
Elekta Unity MR-Linac cleared for diffusion-weighted images to assess tumor response paving the way toward a new era of personalized radiotherapy
Award is one of the highest honors in the category of field service, recognizing commitment to outstanding innovation, leadership and excellence
Elekta announces that its Elekta Unity magnetic resonance radiation therapy system has been awarded the Institute of Physics Business Innovation Award 2019.
Multiple Abstracts Presented at ASTRO Demonstrate the Technical Capabilities and Clinical Utility of the Elekta Unity MR-linac System
Elekta Unity enables anatomic adaptive paradigms while establishing the foundation for biological adaptive paradigms that are the next evolution of precision radiation medicine
Elekta Announces Exclusive Agreement With DOSIsoft for Distribution of Key Patient-specific QA Solutions
Products fill out company's Elekta Assurance portfolio for comprehensive end-to-end quality assurance
Clinical implementation of breakthrough technology that Sunnybrook scientists and physicians helped transform from concept to clinical practice [16-August-2019] TORONTO , Aug. 16, 2019 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre has treated its first patient using Elekta Unity, a transformative
Elekta (EKTA-B.ST) today announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has achieved regulatory certification from the Canadian Nuclear Safety Commission, clearing the technology for clinical use in Canada.
Demonstrates commitment to providing patients with personalized precision radiation medicine for multiple cancer indications
Digital solutions are high on the agenda for most industries, especially within healthcare.
On Friday, April 26, 2019, Elekta Ltd. and its US operating company Elekta, Inc. ("Elekta") filed a lawsuit against ZAP® Surgical Systems in the United States District Court for the Northern District of California.
Elekta (EKTA-B.ST), a pioneer in development of precision radiation therapy, radiosurgery and clinical software for the treatment of cancer and neurological disorders, announced today it has filed a patent infringement lawsuit against ZAP Surgical Systems Inc. in the United States District Court for the Northern District of California.
Elekta to showcase innovative advancements in radiation therapy, offering more personalized and precise solutions with the potential to transform cancer care
New system for the delivery of radiotherapy using magnetic resonance imaging to enhance personalized cancer treatment in Canada
Radiation therapy system delivered to Korea's Hallym University Kangnam Sacred Heart Hospital
Award honors those companies who recognize their critical role to influence and drive positive change in the business community and societies around the world [26-February-2019] STOCKHOLM , Feb. 26, 2019 /PRNewswire/ -- Elekta (EKTA-B.ST), a leader in precision radiation medicine, has been recognized by the Ethisphere Institute, a global leader in defining and advanci
Froedtert & the Medical College of Wisconsin Clinical Cancer Center at Froedtert Hospital Begins Patient Treatments with Elekta Unity MR-linac
Elekta Unity allows treatment to be adapted daily based on tumor status, improving accuracy of radiation delivery to tumor while sparing healthy tissue